Veracyte
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · California, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
6000 Shoreline Ct Ste 300, South San Fra...Phone Number
(650) 243-6300Website
www.veracyte.comRevenue
$541.7 MillionStock Symbol
VCYTIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
5
5
1
2
2
About Veracyte
Founded in 2006, Veracyte is emerging in the field of molecular cytology by developing molecular tests designed to improve the diagnostic accuracy of cytology samples and also helping to increase the utility of minimally invasive procedures as an alternative to surgical biopsy. The company is headquartered in San Francisco, California.Explore more
Veracyte Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Veracyte your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Veracyte had a recent Job posting/layoffs
Earning: See what the market has to say on Veracyte recently announced quarterly report
Funding: Get notified immidiatlly once Veracyte has new funding data
Product Launch: Get notified when Veracyte launches new products
Check if Veracyte has recently received funding, and reach out quickly before it becomes old news!
Veracyte, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Veracyte is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Veracyte
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Veracyte
Compare insights from companies similar to Veracyte, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Veracyte is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Veracyte is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Veracyte.
Veracyte financials insights
Gather financial insights about Veracyte, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Series B
$28M
2013
Series C
$28M
Stock Offering
$58M
2015
Share Placement
$40M
2016
Debt
$45M
Stock Offering
$31.9M
2018
Stock Offering
$55.1M
2019
Stock Offering
$137.9M
2020
Stock Offering
$194M
Veracyte Tech Stack
A closer look at the technologies used by Veracyte
See more technologies
Most Recent Scoops
Hiring Plans
Veracyte has announced plans to hire 10 to 12 sales representatives for its breast cancer sales channel over the course of the current year, with the potential to accelerate hiring if market demand warrants. The initiative will follow a top-down approach targeting key opinion leaders, with performance tracked across an active cohort of 8 key performance indicators.
Hiring Plans, Sales
Project
Veracyte has announced that its Decipher GRID platform, which leverages a whole transcriptome approach reporting on a 22-gene classifier, is actively transitioning additional signatures including PORTOS, PAM50, and P10 from research use only (RUO) status to clinical reporting as supporting clinical utility data matures. Veracyte has also scanned 365,000 images to date and is developing its DPAI (Digital Pathology AI) capability along the same clinical validation pathway, with early findings indicating that DPAI enhances the accuracy of clinical factors rather than providing incremental risk classification information.
Product Development, Medical Research, Artificial Intelligence, Clinical Operations
Product Launch
Veracyte has announced the launch of TruMRD, a whole genome minimal residual disease (MRD) test, with MolDx coverage secured for recurrence monitoring in the prostate cancer setting. Veracyte will deploy TruMRD through its existing Decipher sales channel, which covers approximately 70% of the recurrence monitoring patient population managed by radiation oncologists and urologists.
Earnings
Veracyte has reported that the introduction of its V2 transcriptome has delivered meaningful gross margin improvements by eliminating no-result costs previously absorbed in COGS for approximately 2% to 3% of test volume, while also materially reducing sequencing costs by transitioning from a 2015 to a 2026 sequencing cost structure. These efficiencies have enabled Veracyte to deliver 26% adjusted EBITDA while continuing to invest heavily in new growth initiatives.
Earnings, Spending/Investment, Finance, Financial Operations
Project
Business Development
Veracyte News & Media
What to Know About This $197,000 Veracyte Insider Sale After a 120% Stock Rally
This genomics diagnostics specialist, up over 120% in a year, reported a notable insider sale amid ongoing scheduled dispositions.Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript
Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer June 1, 2026 8:30 AM EDTCompany...Marc Stapley – Chief Executive Officer - CEO - Veracyte
Veracyte Chief Executive Officer, CEO, Marc Stapley, has led the company since 2021 with significant expertise building and leading complex global enterprises.How Veracyte's New AI-Focused CTO Role At Veracyte (VCYT) Has Changed Its Investment Story
Veracyte, Inc. recently appointed Kevin Haas, Ph.D., as its first Chief Development and Technology Officer, tasking him with overseeing end-to-end product development across diagnostic assays, software, bioinformatics and program management to support its expanding global portfolio of laboratory-developed tests and in vitro diagnostic products. This new role, filled by a leader with deep experience in automated lab technology, AI and genomics platforms, underscores Veracyte’s intent to more...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Veracyte
Sign Up For FreeTo access detailed company insights
Founded in 2006, Veracyte is emerging in the field of molecular cytology by developing molecular tests designed to improve the diagnostic accuracy of cytology samples and also helping to increase the utility of minimally invasive procedures as an alternative to surgical biopsy. The company is headquartered in San Francisco, California.... Read More
